BiotechTV

•

Канал • Подкастов: 5

Бионауки

Бионауки

25 июн.
Бионауки

Бионауки

Каждые две недели
Бионауки

Бионауки

31 мая
Бионауки

Бионауки

5 мар.
Бионауки

Бионауки

2 февр.

25 июн.

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.

25 июн.

•

47 мин.
23 апр.

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more.

23 апр.

•

42 мин.
15 июн.

Episode 42: Nextech's Thilo Schroeder

Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.

15 июн.

•

1 ч. 5 мин.
31 мая

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.

31 мая

•

35 мин.
20 апр.

Episode 38: Deerfield Management's Jason Fuller

He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas that interest him today and how he thinks about AI.

20 апр.

•

1 ч. 6 мин.
9 апр.

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him about championing true innovation, and what the word 'innovation' even means in today's environment. Plus, his thoughts on China, drug pricing and access, IP, AI ,and more.

9 апр.

•

34 мин.
10.04.2025

Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs, China, and whether he thinks biotech has a structural problem regarding how companies 'innovate' today and the different market strategies of investors.

10.04.2025

•

34 мин.
1 июн.

Episode 41: Forbion's Nanna Lüneborg

Nanna Luneborg discusses hear career and joining Forbion. She describes the firm's investment approach, and her experience with everything from seed, to private, and to public investing in life sciences. Plus, thoughts on China and AI in biotech.

1 июн.

•

1 ч. 2 мин.
30.06.2025

Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses what qualities make targets attractive, and how the industry has changed over time during the course of his career. Plus, what attracted him to Jefferies.

30.06.2025

•

27 мин.
08.05.2025

Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries

Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his philosophy of writing for investors, and how the business of journalism does and doesn't affect the types of stories he writes.

08.05.2025

•

37 мин.

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Сайт

BiotechTV

Популярные подкасты

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

Episode 42: Nextech's Thilo Schroeder

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

Episode 38: Deerfield Management's Jason Fuller

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

Episode 41: Forbion's Nanna Lüneborg

Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries

Об этом подкасте

BiotechTV

Популярные подкасты

Популярные выпуски

Об этом подкасте